• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Humana and Evolent Expand Partnership to Enhance Oncology Care

    11/7/24 4:15:00 PM ET
    $EVH
    $HUM
    Other Consumer Services
    Consumer Discretionary
    Medical Specialities
    Health Care
    Get the next $EVH alert in real time by email

    Partnership Focuses on Improving Prior Authorization Process, Helping Drive Better Patient Outcomes

    Humana Inc. (NYSE:HUM) and Evolent Health, Inc. (NYSE:EVH) announced they have expanded their strategic medical oncology partnership to modernize and streamline prior authorization processes to include radiation and surgical oncology services. By connecting all primary approaches to treating cancer, this collaboration will help expedite approval of prior authorization requests, improve patient access to care, and ensure timely access to critical treatments.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241107578119/en/

    "This partnership underscores our commitment to delivering a better healthcare experience and, most importantly, better health outcomes for our members," said Paul Davis, Vice President of National Provider Network Management at Humana. "Our members who need radiation and oncology care deserve access to high-quality, timely care, and this collaboration will help give them the support and care they need."

    Humana is working to simplify the prior authorization process by leveraging Evolent's advanced technology platform and expertise across the patient's cancer journey. Through the Evolent platform, providers can access the most up-to-date, clinically appropriate therapy choices for specific clinical scenarios. Prior authorization requests are submitted in minutes and approvals are delivered in seconds. This connected experience, which is well organized, simple to navigate and CMS compliant, will reduce administrative burdens for both providers and patients and ensure that Humana members receive timely access to high-quality care.

    "We are thrilled to continue partnering with Humana to drive meaningful change across the continuum of oncology care," said Dan McCarthy, President at Evolent, a health care company that delivers proven value-based specialty care solutions to payers and providers. "Building upon our longstanding work with Humana in medical oncology, this national expansion into radiation therapies and surgical procedures will help enable a more coordinated, high-quality, and efficient experience for both members and providers throughout the cancer journey."

    Under the expanded partnership, Evolent will serve as Humana's designated utilization management and pathway vendor for radiation and surgical oncology services. The partnership represents a significant milestone in modernizing authorization processes and underscores both companies' dedication to improving healthcare outcomes.

    About Humana

    Humana Inc. is committed to putting health first – for our teammates, customers, and company. Through our Humana insurance services and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.

    About Evolent

    Evolent (NYSE:EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolent.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241107578119/en/

    Get the next $EVH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVH
    $HUM

    CompanyDatePrice TargetRatingAnalyst
    Evolent Health Inc
    $EVH
    2/25/2026Overweight → Sector Weight
    KeyBanc Capital Markets
    Humana Inc.
    $HUM
    2/12/2026$189.00Outperform → Sector Perform
    RBC Capital Mkts
    Humana Inc.
    $HUM
    2/2/2026$174.00Equal-Weight → Underweight
    Morgan Stanley
    Humana Inc.
    $HUM
    1/7/2026$290.00Overweight → Equal Weight
    Wells Fargo
    Humana Inc.
    $HUM
    12/5/2025$313.00Hold → Buy
    Jefferies
    Evolent Health Inc
    $EVH
    11/13/2025$7.00Equal-Weight → Overweight
    Stephens
    Evolent Health Inc
    $EVH
    11/13/2025$7.00Outperform
    BMO Capital Markets
    Humana Inc.
    $HUM
    10/14/2025$235.00Sell
    Goldman
    More analyst ratings

    $EVH
    $HUM
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Evolent Health Inc

    SCHEDULE 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    3/26/26 6:20:05 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Humana Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - HUMANA INC (0000049071) (Filer)

    3/9/26 4:22:23 PM ET
    $HUM
    Medical Specialities
    Health Care

    SEC Form DEFR14A filed by Humana Inc.

    DEFR14A - HUMANA INC (0000049071) (Filer)

    3/6/26 5:31:00 PM ET
    $HUM
    Medical Specialities
    Health Care

    $EVH
    $HUM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evolent announces appointment of Archie Mayani as chief product officer

    Industry veteran brings track record of innovation from GHX, Change Healthcare, UnitedHealth Group and Amazon.WASHINGTON, March 19, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced the appointment of health care technology leader and AI innovator Archie Mayani as chief product officer (CPO).Mayani brings more than two decades of leadership experience across health care, enterprise platforms, and AI, with a history of building products that improve clinical and business outcomes at scale.Before joining Evolent, she served as CPO at GHX, where she helped pioneer AI-powered capabilitie

    3/19/26 8:45:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Foodsmart Appoints Cityblock Health Co-Founder and CEO Dr. Toyin Ajayi to Board of Directors

    National leader in value-based care joins as Foodsmart scales foodcare for Medicaid populationsSAN FRANCISCO, March 18, 2026 /PRNewswire/ -- Foodsmart, the leading telenutrition and foodcare provider nationwide, today announced the appointment of Dr. Toyin Ajayi to its Board of Directors. A board-certified Family Medicine physician and the co-founder and CEO of Cityblock Health, Dr. Ajayi brings deep experience serving Medicaid and dually eligible populations through value-based care models designed to improve outcomes and lower total cost of care. For millions of Americans, foo

    3/18/26 9:11:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Continuous Glucose Monitoring on the Rise Among Medicare Advantage Members with Type 2 Diabetes

    Study by Humana Healthcare Research and Yale School of Medicine researcher reveals significant increase in CGM usage, particularly among older adults with chronic health conditions. A new study published in the current issue of the Journal of Managed Care & Specialty Pharmacy (JMCP)—conducted by a Humana Healthcare Research team and Dr. Joseph S. Ross of the Yale School of Medicine—reveals a notable increase in the use of continuous glucose monitors (CGMs) among Medicare Advantage members with type 2 diabetes from 2021 to 2023. The study also compared the demographic and clinical characteristics of members with type 2 diabetes who used CGMs with those who did not in 2023, finding that t

    3/12/26 9:30:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    $EVH
    $HUM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evolent Health downgraded by KeyBanc Capital Markets

    KeyBanc Capital Markets downgraded Evolent Health from Overweight to Sector Weight

    2/25/26 7:39:36 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Humana downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Humana from Outperform to Sector Perform and set a new price target of $189.00

    2/12/26 8:16:45 AM ET
    $HUM
    Medical Specialities
    Health Care

    Humana downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Humana from Equal-Weight to Underweight and set a new price target of $174.00

    2/2/26 6:49:06 AM ET
    $HUM
    Medical Specialities
    Health Care

    $EVH
    $HUM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, CenterWell Shetty Sanjay K bought $150,016 worth of Humana Common (810 units at $185.21), increasing direct ownership by 7% to 11,657 units (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/25/26 11:48:38 AM ET
    $HUM
    Medical Specialities
    Health Care

    Director Springstubb Brendan B bought $38,199 worth of shares (10,000 units at $3.82), increasing direct ownership by 20% to 58,821 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    11/19/25 4:23:02 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    President & CEO Rechtin James A. bought $1,496,984 worth of Humana Common (6,530 units at $229.25) (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    5/16/25 4:48:13 PM ET
    $HUM
    Medical Specialities
    Health Care

    $EVH
    $HUM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Blackley Seth covered exercise/tax liability with 51,326 shares and was granted 58,921 shares, increasing direct ownership by 0.92% to 836,962 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/4/26 6:02:31 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    General Counsel Weinberg Jonathan was granted 4,910 shares and covered exercise/tax liability with 14,577 shares, decreasing direct ownership by 4% to 244,512 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/4/26 5:58:37 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    PRESIDENT Mccarthy Daniel Joseph covered exercise/tax liability with 50,030 shares and was granted 39,281 shares, decreasing direct ownership by 2% to 423,022 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/4/26 5:53:20 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    $HUM
    Leadership Updates

    Live Leadership Updates

    View All

    Evolent announces appointment of Archie Mayani as chief product officer

    Industry veteran brings track record of innovation from GHX, Change Healthcare, UnitedHealth Group and Amazon.WASHINGTON, March 19, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced the appointment of health care technology leader and AI innovator Archie Mayani as chief product officer (CPO).Mayani brings more than two decades of leadership experience across health care, enterprise platforms, and AI, with a history of building products that improve clinical and business outcomes at scale.Before joining Evolent, she served as CPO at GHX, where she helped pioneer AI-powered capabilitie

    3/19/26 8:45:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Foodsmart Appoints Cityblock Health Co-Founder and CEO Dr. Toyin Ajayi to Board of Directors

    National leader in value-based care joins as Foodsmart scales foodcare for Medicaid populationsSAN FRANCISCO, March 18, 2026 /PRNewswire/ -- Foodsmart, the leading telenutrition and foodcare provider nationwide, today announced the appointment of Dr. Toyin Ajayi to its Board of Directors. A board-certified Family Medicine physician and the co-founder and CEO of Cityblock Health, Dr. Ajayi brings deep experience serving Medicaid and dually eligible populations through value-based care models designed to improve outcomes and lower total cost of care. For millions of Americans, foo

    3/18/26 9:11:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Humana Announces Insurance Leadership Transition

    George Renaudin to Retire as Insurance Segment President by Q3 2026 Aaron Martin to Join as President of Medicare Advantage and Insurance Segment President Successor John Barger to Succeed Martin as President of Medicare Advantage Humana Inc. (NYSE:HUM) today announced that George Renaudin, Insurance Segment President and member of Humana's Enterprise Leadership Team, will retire by Q3 2026 following a successful 29-year career at the company. During this period, Renaudin played a pivotal role in establishing and growing Humana's Medicare Advantage and Medicaid programs, helping to build them into high-performing businesses and assembling a strong insurance leadership team. "George has co

    12/16/25 8:05:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    $EVH
    $HUM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    11/12/24 9:55:15 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    8/7/24 7:47:40 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    7/10/24 10:10:34 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    $HUM
    Financials

    Live finance-specific insights

    View All

    Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results

    WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended December 31, 2025.Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "In 2025 we executed on our earnings targets, continued to grow market share, renewed customers at strong rates, and continued the migration of Performance Suite clients to our enhanced Performance Suite contract model. We believe our total forecasted revenue growth of approximat

    2/24/26 4:10:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Humana Board Declares Payment of Quarterly Dividend to Stockholders

    Humana Inc. (NYSE:HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on April 24, 2026 to stockholders of record as of the close of business on March 27, 2026. About Humana Humana (NYSE:HUM) is a leading U.S. healthcare company. Through our Humana insurance services and our CenterWell healthcare services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare and Medicaid, families, individuals, military service personnel, and communities at large.

    2/19/26 6:30:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Humana Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Financial Guidance

    Reports 4Q25 net loss per share of $6.61 on a GAAP basis, Adjusted net loss per share of $3.96; reports full year (FY) 2025 earnings per share (EPS) of $9.84 on a GAAP basis, $17.14 on an Adjusted basis; quarterly and FY Adjusted results in line with management's expectations 4Q25 Insurance segment GAAP benefit ratio of 93.1 percent; FY 2025 Insurance segment GAAP benefit ratio of 90.4 percent, slightly better than guidance of 'the top end of the range of 90.1 percent to 90.5 percent' Introduces FY 2026 GAAP EPS guidance of 'at least $8.89'; 'at least $9.00' on an Adjusted basis; the anticipated year-over-year decline results from the Star Ratings headwind for Bonus Year 2026, net of

    2/11/26 6:00:00 AM ET
    $HUM
    Medical Specialities
    Health Care